Galena Biopharma Inc
Change company Symbol lookup
Select an option...
GALE Galena Biopharma Inc
LL Lumber Liquidators Holdings Inc
CECE CECO Environmental Corp
APA Apache Corp
NSEC.ZY National Security Group Inc
CYN-D City National Corp
WAFD Washington Federal Inc
CYTK Cytokinetics Inc
CFC-B Countrywide Capital V
ACSF American Capital Senior Floating Ltd
Go

Health Care : Biotechnology | Small Cap BlendCompany profile

Galena Biopharma, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets, including immunotherapy program led by its lead product NeuVax (nelipepimut-S), which is in Phase III clinical trial and is a targeted cancer immunotherapy. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drugs include Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain and Zuplenz (ondansetron) Oral Soluble Film is approved by the Food and Drug Administration in adult patients for the prevention of emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting.

Closing Price
$1.62
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0
10-day average volume:
1,806,505
0
  • Prev Close
    1.62
  • Today's Open
    0.00
  • Day's Range
    --
  • Avg Vol (10-day)
    1.8M
  • Last (time)
    4:00p ET 09/03/15
  • Last (size)
    37.9K
  • 52-Wk Range
    1.10 - 2.50
    LowHigh
  • (09/08/14 - 08/24/15)
    47.27%
  • 63.5%
  • Market Cap
    262.0M
  • Shares Outstanding
    161.7M
  • -0.29
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 0.4
  • 16.57
  • (% of float 08/15/15)
    13.91

Latest News

September 01, 2015
7:05 am ET
Globe Newswire
August 31, 2015
11:00 am ET
PR Newswire
August 24, 2015
7:05 am ET
Globe Newswire
August 06, 2015
4:18 pm ET
Globe Newswire
August 05, 2015
10:03 am ET
Globe Newswire
July 29, 2015
7:05 am ET
Globe Newswire
July 28, 2015
7:05 am ET
Globe Newswire
July 17, 2015
9:25 am ET
PR Newswire
June 15, 2015
7:05 am ET
Globe Newswire
April 03, 2015
10:16 am ET
MarketWatch
10:16 am ET
MarketWatch
March 18, 2015
9:42 am ET
MarketWatch
9:42 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2015 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Thomson Reuters; © Thomson Reuters Limited

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by , Computrade Systems, Inc.,, , and

Copyright © 2015. All rights reserved.